Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
KT-621 by Kymera Therapeutics for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
KT-621 is under clinical development by Kymera Therapeutics and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to...